| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
The specific molecular targets of kaempferol 3-sophoroside-7-glucoside have not been fully elucidated. As a flavonoid glycoside, it is likely to interact with multiple cellular targets involved in metabolic regulation. The compound is classified under "Others" in target pathway classifications. Based on its anti-obesity activity, it may modulate pathways related to lipid metabolism and energy homeostasis. Flavonoids of this class are known to interact with various enzymes and receptors involved in inflammation and metabolic syndrome, though specific binding affinities for this particular glycoside remain to be characterized.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that kaempferol 3-sophoroside-7-glucoside exhibits anti-obesity activity. As a bioactive component of roasted Lycium chinense leaves, the compound has been shown to possess biological activities consistent with other flavonoid glycosides, including antioxidant properties. The compound's in vitro activity is typically evaluated using cell-based assays measuring adipocyte differentiation, lipid accumulation, or inflammatory marker expression. However, specific IC50 values and detailed mechanistic data for this particular compound are limited in the published literature.
|
| ln Vivo |
In vivo studies have shown that kaempferol 3-sophoroside-7-glucoside exhibits anti-obesity activity. The compound is a bioactive component found in roasted Lycium chinense leaves that has been associated with weight management effects. Animal model studies using the parent compound or extracts containing this flavonoid have demonstrated reductions in body weight and improvements in metabolic parameters. However, detailed pharmacokinetic and pharmacodynamic data specific to this compound in animal models are not extensively documented in the available literature.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding assay for kaempferol 3-sophoroside-7-glucoside typically involves radioligand binding or fluorescence-based competition assays using purified enzymes or receptor preparations. The compound is incubated with the target protein at varying concentrations (typically 0.1 nM to 100 uM) in appropriate buffer systems. After incubation at room temperature or 37degC for 1-4 hours, bound and free ligand are separated by filtration or centrifugation, and binding affinity (Kd or IC50) is determined by nonlinear regression analysis. Non-specific binding is determined in the presence of excess unlabeled competitor.
|
| Cell Assay |
In vitro cellular assays for kaempferol 3-sophoroside-7-glucoside are typically conducted using adipocyte or hepatocyte cell lines. Cells are seeded in 96-well or 24-well plates and treated with varying concentrations of the compound (typically 1-100 uM) for 24-72 hours. Adipocyte differentiation is assessed by Oil Red O staining and quantification of lipid accumulation. Cell viability is monitored using MTT or CCK-8 assays to ensure observed effects are not due to cytotoxicity. Inflammatory markers such as TNF-alpha, IL-6, and MCP-1 are measured by ELISA in cell culture supernatants. Gene expression analysis by qPCR is used to assess changes in metabolic and inflammatory pathways.
|
| Animal Protocol |
In vivo animal experiments for kaempferol 3-sophoroside-7-glucoside typically involve oral administration to rodent models of obesity or metabolic syndrome. Mice or rats are fed a high-fat diet to induce obesity, then treated with the compound (typically 10-100 mg/kg/day) by oral gavage for 4-8 weeks. Body weight, food intake, and adipose tissue weights are monitored throughout the study. At the end of the treatment period, blood samples are collected for analysis of glucose, insulin, lipid profiles, and inflammatory cytokines. Liver and adipose tissues are harvested for histopathological examination and gene expression analysis by qPCR or Western blotting.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of kaempferol 3-sophoroside-7-glucoside are not extensively documented. As a flavonoid glycoside with high molecular weight (772.66) and multiple sugar moieties, the compound is expected to have limited oral bioavailability due to poor intestinal absorption and extensive first-pass metabolism. The compound is typically formulated for in vivo administration using DMSO-based vehicles. The solubility in DMSO is reported, and various injection formulations have been described for research applications. The compound is stable as a powder at -20degC for up to 3 years and in solution at -80degC for 6 months.
|
| Toxicity/Toxicokinetics |
Toxicological data for kaempferol 3-sophoroside-7-glucoside are limited. As a naturally occurring flavonoid glycoside found in edible plants including Lycium chinense leaves and Brassica species, the compound is generally considered to have low toxicity. The compound is supplied for research use only and is not intended for human therapeutic use. Standard toxicity screening would typically include assessment of cell viability in vitro using MTT or similar assays, and in vivo evaluation of general toxicity parameters including body weight, organ weights, and clinical chemistry in rodent models. No specific LD50 values or detailed toxicity profiles have been reported in the available literature.
|
| References | |
| Additional Infomation |
It has been reported that poppies, saffron, and other organisms with available data contain kaempferol 3-sophoroside-7-glucoside.
Kaempferol 3-sophoroside-7-glucoside (CAS 55136-76-0) is a flavonoid glycoside classified as a natural product. The compound has the IUPAC name 3-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one. It is a bioactive component in roasted Lycium chinense leaves with documented anti-obesity activity. The compound is available for research purposes only and should be stored as a powder at -20degC. |
| Molecular Formula |
C33H40O21
|
|---|---|
| Molecular Weight |
772.6581
|
| Exact Mass |
772.206
|
| CAS # |
55136-76-0
|
| PubChem CID |
12960460
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
-2.7
|
| Hydrogen Bond Donor Count |
13
|
| Hydrogen Bond Acceptor Count |
21
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
54
|
| Complexity |
1300
|
| Defined Atom Stereocenter Count |
15
|
| SMILES |
C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)O
|
| InChi Key |
MBFNAZBJKVFNKZ-JGPRCQAHSA-N
|
| InChi Code |
InChI=1S/C33H40O21/c34-7-15-19(39)23(43)26(46)31(50-15)48-12-5-13(38)18-14(6-12)49-28(10-1-3-11(37)4-2-10)29(22(18)42)53-33-30(25(45)21(41)17(9-36)52-33)54-32-27(47)24(44)20(40)16(8-35)51-32/h1-6,15-17,19-21,23-27,30-41,43-47H,7-9H2/t15-,16-,17-,19-,20-,21-,23+,24+,25+,26-,27-,30-,31-,32+,33+/m1/s1
|
| Chemical Name |
3-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2942 mL | 6.4712 mL | 12.9423 mL | |
| 5 mM | 0.2588 mL | 1.2942 mL | 2.5885 mL | |
| 10 mM | 0.1294 mL | 0.6471 mL | 1.2942 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
